Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	2154-2156
Number of pages	3
Journal	Translational Cancer Research
Volume	9
Issue number	4
DOIs	https://doi.org/10.21037/tcr.2020.03.07
State	Published - Apr 1 2020
Externally published	Yes

ASJC Scopus subject areas

@article{5c14db3878ac469295cf3ddb8f04f049,

title = "Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment",

author = "Shibani Mukherjee and Aroumougame Asaithamby",

year = "2020",

month = apr,

day = "1",

doi = "10.21037/tcr.2020.03.07",

language = "English (US)",

volume = "9",

pages = "2154--2156",

journal = "Translational Cancer Research",

issn = "2218-676X",

publisher = "AME Publishing Company",

number = "4",

}

TY - JOUR

T1 - Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment

AU - Mukherjee, Shibani

AU - Asaithamby, Aroumougame

PY - 2020/4/1

Y1 - 2020/4/1

UR - https://www.scopus.com/pages/publications/85085955188

UR - https://www.scopus.com/pages/publications/85085955188#tab=citedBy

U2 - 10.21037/tcr.2020.03.07

DO - 10.21037/tcr.2020.03.07

M3 - Comment/debate

AN - SCOPUS:85085955188

SN - 2218-676X

VL - 9

SP - 2154

EP - 2156

JO - Translational Cancer Research

JF - Translational Cancer Research

IS - 4

ER -